AlphaOne Investment Services LLC boosted its stake in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 25.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 66,105 shares of the specialty pharmaceutical company’s stock after buying an additional 13,500 shares during the period. AlphaOne Investment Services LLC owned about 0.19% of AMAG Pharmaceuticals worth $2,301,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Palo Alto Investors LLC increased its position in shares of AMAG Pharmaceuticals by 12.6% in the second quarter. Palo Alto Investors LLC now owns 3,273,220 shares of the specialty pharmaceutical company’s stock valued at $78,295,000 after buying an additional 367,026 shares during the last quarter. BlackRock Fund Advisors increased its position in shares of AMAG Pharmaceuticals by 5.5% in the third quarter. BlackRock Fund Advisors now owns 3,164,395 shares of the specialty pharmaceutical company’s stock valued at $77,559,000 after buying an additional 163,791 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its position in shares of AMAG Pharmaceuticals by 14.1% in the second quarter. Adage Capital Partners GP L.L.C. now owns 2,568,200 shares of the specialty pharmaceutical company’s stock valued at $61,431,000 after buying an additional 316,393 shares during the last quarter. Morgan Stanley increased its position in shares of AMAG Pharmaceuticals by 5.3% in the third quarter. Morgan Stanley now owns 1,027,673 shares of the specialty pharmaceutical company’s stock valued at $25,188,000 after buying an additional 52,098 shares during the last quarter. Finally, Falcon Point Capital LLC increased its position in shares of AMAG Pharmaceuticals by 23.8% in the third quarter. Falcon Point Capital LLC now owns 881,026 shares of the specialty pharmaceutical company’s stock valued at $22,642,000 after buying an additional 169,254 shares during the last quarter.

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) traded up 3.64% on Thursday, hitting $24.20. 1,200,974 shares of the stock were exchanged. AMAG Pharmaceuticals, Inc. has a 52 week low of $17.92 and a 52 week high of $36.83. The company’s 50-day moving average is $25.67 and its 200-day moving average is $27.08. The company’s market cap is $828.95 million.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its earnings results on Tuesday, February 14th. The specialty pharmaceutical company reported ($0.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.85 by $2.16. AMAG Pharmaceuticals had a net margin of 3.12% and a return on equity of 11.10%. The firm had revenue of $151.60 million for the quarter, compared to the consensus estimate of $155.12 million. During the same period in the prior year, the business earned $1.12 EPS. The company’s quarterly revenue was up 39.5% compared to the same quarter last year. On average, analysts predict that AMAG Pharmaceuticals, Inc. will post $6.00 earnings per share for the current year.

“AlphaOne Investment Services LLC Has $2,301,000 Position in AMAG Pharmaceuticals, Inc. (AMAG)” was originally published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was illegally copied and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at http://www.watchlistnews.com/alphaone-investment-services-llc-has-2301000-position-in-amag-pharmaceuticals-inc-amag/1120977.html.

Several research analysts recently weighed in on AMAG shares. Zacks Investment Research downgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, January 9th. Cantor Fitzgerald set a $25.00 target price on shares of AMAG Pharmaceuticals and gave the company a “hold” rating in a research note on Thursday, February 2nd. Needham & Company LLC started coverage on shares of AMAG Pharmaceuticals in a research note on Wednesday, October 26th. They issued a “buy” rating and a $40.00 target price for the company. Cowen and Company downgraded shares of AMAG Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, February 3rd. Finally, Raymond James Financial, Inc. reissued an “underperform” rating on shares of AMAG Pharmaceuticals in a research note on Monday, January 9th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the stock. AMAG Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $31.20.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

5 Day Chart for NASDAQ:AMAG

Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.